Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CETO PET/CT for Subtype Diagnosis of Primary Aldosteronism
NCT05472493Phase 2Recruiting
- Sponsor
- University of Calgary
- Start
- Jan 2023
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]CETO in primary aldosteronism (PA), sponsored by University of Calgary. Primary endpoint: Diagnostic test accuracy (sensitivity, specificity, positive predictive value, and negative predictive value). Started Jan 2023; status: recruiting.
02
Drugs
[18F]CETO
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT05472493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472493.